Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;1(1):7.
doi: 10.1186/s44201-022-00004-7. Epub 2022 Jun 20.

Emergency management of incidental pulmonary embolism (IPE)

Affiliations
Review

Emergency management of incidental pulmonary embolism (IPE)

Carme Font et al. Emerg Cancer Care. 2022.

Abstract

Venous thrombo-embolic (VTE) disease is a common cause of complications in patients with cancer and is the second most common cause of death in oncology patients other than the malignant disease. Whilst symptomatic VTE comprises the majority of such presentations to an emergency department (ED), incidental pulmonary embolism (IPE) is an increasingly frequent reason for attendance. Many studies report that the consequences of IPE do not differ significantly from those with symptomatic presentations and thus most guidelines recommend using the same approach. The complexity of treatment in cancer patients due to increased prevalence of co-morbidities, higher risk of bleeding, abnormal platelet and renal function, greater risk of VTE recurrence, and medications with the risk of anticoagulant interaction are consistent across patients with symptomatic and IPE. One of the initial challenges of the management of IPE is the design of a pathway that provides both patients and clinicians with a seamless journey from the radiological diagnosis of IPE to their initial clinical workup and management. Increased access to ambulatory care has successfully reduced ED utilisation and improved clinical outcomes in high-risk non-oncological populations, such as those with IPE. In this clinical review, we consider IPE management, its workup, the conundrums it may present for emergency physicians and the need to consider emergency ambulatory care for this growing cohort of patients.

Keywords: Ambulatory care; Anticoagulation; Cancer; Incidental pulmonary embolism.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Proposed algorithm for the evaluation of patients with IPE

Similar articles

Cited by

References

    1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634. doi: 10.1111/j.1538-7836.2007.02374.x. - DOI - PubMed
    1. Fernandes C, Morinaga L, Alves J, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151):180119. doi: 10.1183/16000617.0119-2018. - DOI - PMC - PubMed
    1. Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer. 2021;9(1):e001719. doi: 10.1136/jitc-2020-001719. - DOI - PMC - PubMed
    1. Gong J, Drobni Z, Alvi R, et al. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021;158:99–110. doi: 10.1016/j.ejca.2021.09.010. - DOI - PMC - PubMed
    1. Klok F, Huisman MV. Management of incidental pulmonary embolism. Eur Respir J. 2017;49(6):1700275. doi: 10.1183/13993003.00275-2017. - DOI - PubMed

LinkOut - more resources